{"id":"NCT01292473","sponsor":"Genentech, Inc.","briefTitle":"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","officialTitle":"A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2011-02-09","resultsPosted":"2013-09-02","lastUpdate":"2013-10-11"},"enrollment":323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Urticaria"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Omalizumab","otherNames":["Xolair"]}],"arms":[{"label":"Placebo","type":"EXPERIMENTAL"},{"label":"Omalizumab 75 mg","type":"EXPERIMENTAL"},{"label":"Omalizumab 150 mg","type":"EXPERIMENTAL"},{"label":"Omalizumab 300 mg","type":"EXPERIMENTAL"}],"summary":"The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged 12-75 who have been diagnosed with refractory CIU and who remain symptomatic despite standard-dosed H1 antihistamine treatment.","primaryOutcome":{"measure":"Change From Baseline in the Weekly Itch Severity Score at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-5.14,"sd":5.58},{"arm":"Omalizumab 75 mg","deltaMin":-5.87,"sd":6.45},{"arm":"Omalizumab 150 mg","deltaMin":-8.14,"sd":6.44},{"arm":"Omalizumab 300 mg","deltaMin":-9.77,"sd":5.95}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4637"},{"comp":"OG000 vs OG002","p":"0.0011"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":18},"locations":{"siteCount":61,"countries":["United States","Denmark","France","Germany","Italy","Poland","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["39193419","29655772","28390587","27939380","27540466","27424128","26054553","23432142"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":79},"commonTop":["Nasopharyngitis","Headache","Idiopathic urticaria","Upper respiratory tract infection","Influenza"]}}